PDS Biotechnology (NASDAQ:PDSB) Trading 5% Higher – Here’s Why

PDS Biotechnology Corporation (NASDAQ:PDSB)’s stock price rose 5% during trading on Wednesday . The company traded as high as $0.9898 and last traded at $0.9530. Approximately 498,386 shares traded hands during trading, an increase of 16% from the average daily volume of 428,997 shares. The stock had previously closed at $0.9076.

Analysts Set New Price Targets

A number of analysts recently commented on PDSB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Wednesday, October 8th. B. Riley reduced their price objective on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, November 25th. Finally, HC Wainwright lifted their target price on shares of PDS Biotechnology from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Up 5.0%

The company has a debt-to-equity ratio of 1.26, a current ratio of 2.09 and a quick ratio of 2.09. The stock has a market cap of $46.68 million, a price-to-earnings ratio of -1.16 and a beta of 1.12. The firm’s 50-day moving average is $0.87 and its 200 day moving average is $1.05.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.02. Sell-side analysts anticipate that PDS Biotechnology Corporation will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tempus Wealth Planning LLC lifted its stake in shares of PDS Biotechnology by 154.3% in the 2nd quarter. Tempus Wealth Planning LLC now owns 47,800 shares of the company’s stock valued at $64,000 after purchasing an additional 29,000 shares in the last quarter. Watts Gwilliam & Co. LLC purchased a new position in PDS Biotechnology in the second quarter valued at approximately $73,000. Iron Gate Global Advisors LLC acquired a new position in PDS Biotechnology during the first quarter valued at approximately $89,000. Marshall Wace LLP purchased a new stake in PDS Biotechnology during the second quarter worth approximately $91,000. Finally, Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the second quarter worth $92,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.